Doximity: Elite Margins, AI Growth, And An Attractive Multiple

Doximity's Q2 results show record engagement and accelerating adoption of AI workflow tools, signaling deeper physician reliance on the platform. Revenue quality is improving as pharma clients shift from one-off ad buys to longer-term integrated programs. Doximity has a strong Rule-of-50 profile with high margins and $890m cash but no debt.

Seeking Alpha • Dec 7, 2025

Here's Why Doximity (DOCS) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 28, 2025

Wall Street is Pounding the Table Over NVDA, CVNA, DOCS

CVNA last traded at $313.25 a share after finding support at $285.02, which was double-bottom support dating back to June 2025.

24/7 Wall Street • Nov 21, 2025

Why Doximity (DOCS) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 12, 2025

Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y

DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.

Zacks Investment Research • Nov 7, 2025

Doximity, Inc. (DOCS) Q2 2026 Earnings Call Transcript

Doximity, Inc. ( DOCS ) Q2 2026 Earnings Call November 6, 2025 5:00 PM EST Company Participants Perry Gold - Head of Investor Relations Jeffrey Tangney - Co-Founder, CEO & Chairperson Anna Bryson - Chief Financial Officer Conference Call Participants Brian Peterson - Raymond James & Associates, Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Allen Lutz - BofA Securities, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Craig Hettenbach - Morgan Stanley, Research Division Derek Gross - Piper Sandler & Co., Research Division Brian Tanquilut - Jefferies LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division David Roman - Goldman Sachs Group, Inc., Research Division Eric Percher - Nephron Research LLC Jenny Shen - BTIG, LLC, Research Division Jenny Cao - Truist Securities, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.

Seeking Alpha • Nov 7, 2025

Doximity Announces Fiscal 2026 Second Quarter Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025. “Our platform continues to grow with new AI tools to save physicians' time,” said Jeff Tangney, co-founder and CEO of Doximity. “In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients, while our AI Scribe and DoxGPT users grew over 50% from the prior quarte.

Business Wire • Nov 6, 2025

Compared to Estimates, Doximity (DOCS) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Nov 7, 2025

Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates

Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.3 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Doximity (DOCS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 30, 2025